

NCCN Neuroendocrine Tumors Guidelines V.1.2011 – Update Teleconference – 09/29/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>CARC-5 External request: Submission from Novartis Oncology to add everolimus as an option for patients with advanced carcinoid tumors.</p>	<p>Based on the noted reference, the panel consensus was to add everolimus as an option for patients with advanced carcinoid tumors with a category 3 designation.</p>	<p>Yao JC, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2) [abstract]. J Clin Oncol 2011;29 (suppl 4):159. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71040.</p>	14	2	1
<p>CARC-5 and PancNET-5 Internal request: Panel discussion comment to reorganize the algorithm for the management of locoregional unresectable disease and/or distant metastases.</p>	<p>Based on panel consensus and the reorganization of the recommendations based on disease status rather than metastatic site, bisphosphonates (pamidronate disodium, zoledronic acid) in combination with radiation therapy were removed from the guideline.</p>		17	0	0
<p>PancNET-1 Internal request: Panel discussion comment for the inclusion of octreotide acetate for the management of primary nonmetastatic gastrinoma.</p>	<p>Based on panel consensus and supported by the noted references, octreotide acetate was added as an option for the management of primary nonmetastatic gastrinoma.</p>	<p>Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-542. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11459269.</p> <p>Fjallskog ML, Sundin A, Westlin JE, et al. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12025889.</p>	17	0	0

NCCN Neuroendocrine Tumors Guidelines V.1.2011 – Update Teleconference – 09/29/10

<p>PancNET-2 Internal request: Panel discussion comment to remove octreotide acetate for the management of primary nonmetastatic insulinoma.</p>	<p>Based on panel consensus and supported by the noted reference, octreotide acetate was removed as a management option for primary nonmetastatic insulinoma.</p>	<p>Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 1989;121:34-40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2545062</p>	<p>17</p>	<p>0</p>	<p>0</p>
--	---	--	-----------	----------	----------